Skip to Content

Join the 'Amigesic' group to help and get support from people like you.

Amigesic News

Pain Reliever Lowers Blood Sugar in Type 2 Diabetics, Study Says

Posted 1 Jul 2013 by Drugs.com

MONDAY, July 1 – An aspirin-like drug appears to lower blood sugar in people with type 2 diabetes, according to new research. A study of the drug – the prescription pain reliever salsalate – also found it reduced inflammation associated with type 2 diabetes. But it produced unwelcome side effects that could limit its potential as a diabetes treatment. "This trial is a test of possibly the oldest drug in Western use, and, because it's so old, there are no clinical trials on it," said study senior author Dr. Steven Shoelson, a professor of medicine at Harvard Medical School in Boston. "This trial was for a full year and showed that salsalate does lower blood glucose," said Shoelson, who is also the associate research director at the Joslin Diabetes Center in Boston. The study, published in the July 2 issue of the Annals of Internal Medicine, included 286 people between 18 and 75 years ... Read more

Related support groups: Diabetes, Type 2, Salsalate, Argesic-SA, Marthritic, Salflex, Anaflex, Disalcid, Mono-Gesic, Salsitab, Amigesic

Arthritis Drug May Fight Diabetes, Too

Posted 15 Mar 2010 by Drugs.com

MONDAY, March 15 – A generic drug widely prescribed for arthritis shows promise in treating type 2 diabetes, according to U.S. researchers. They found that salsalate – an atypical non-steroidal anti-inflammatory drug, chemically similar to aspirin but easier on the stomach – helps control glucose levels. The finding came from a three-month clinical trial of 108 people, 18 to 75 years old, who had type 2 diabetes. Those who took salsalate, the study found, had a 0.5 percent drop in levels of hemoglobin A1C, a measure of blood glucose levels. The decrease was in the range of several recently released diabetes treatments, according to the study, led by Joslin Diabetes Center researchers. The findings are published online March 16 in Annals of Internal Medicine. "These results are exciting," Dr. Allison Goldfine, director of clinical research at Joslin and an associate professor at ... Read more

Related support groups: Diabetes, Type 2, Salsalate, Argesic-SA, Marthritic, Salflex, Anaflex, Disalcid, Mono-Gesic, Salsitab, Amigesic

FDA Medwatch Alert: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Posted 7 Apr 2005 by Drugs.com

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: * The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery (CABG) trials that FDA believes may be relevant to chronic use. * Reports of serious and potentially life-threatening skin reactions, including deaths, in patients using Bextra. The risk of these reactions in individual patients is unpredictable, occurring in patients with and without a prior history of sulfa allergy, and after both short- and long-term use. * Lack of any demonstrated advantages for Bextra compared with other NSAIDs. Patients currently taking Bextra should contact their physicians to ... Read more

Related support groups: Advil, Mobic, Toradol, Relafen, Lodine, Indocin, Cataflam, Feldene, Daypro, Ponstel, Ansaid, Dolobid, Nalfon, Clinoril, Actron, Aflaxen, Amigesic, Tolectin

FDA Medwatch Alert: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Posted 15 Jun 2005 by Drugs.com

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: * The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery (CABG) trials that FDA believes may be relevant to chronic use. * Reports of serious and potentially life-threatening skin reactions, including deaths, in patients using Bextra. The risk of these reactions in individual patients is unpredictable, occurring in patients with and without a prior history of sulfa allergy, and after both short- and long-term use. * Lack of any demonstrated advantages for Bextra compared with other NSAIDs. Patients currently taking Bextra should contact their physicians to ... Read more

Related support groups: Celebrex, Advil, Mobic, Toradol, Relafen, Lodine, Indocin, Vioxx, Cataflam, Feldene, Daypro, Ponstel, Ansaid, Dolobid, Nalfon, Clinoril, Bextra, Actron, Tolectin, Aflaxen

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis, Osteoarthritis

Amigesic Patient Information at Drugs.com